Candel Therapeutics
CADL
22 hedge funds and large institutions have $5.92M invested in Candel Therapeutics in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
22% more capital invested
Capital invested by funds: $4.86M → $5.92M (+$1.06M)
10% more funds holding
Funds holding: 20 → 22 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.26% less ownership
Funds ownership: 18.18% → 13.93% (-4.3%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.1K |
| 2 |
Renaissance Technologies
New York
|
+$18.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$16K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$11.6K |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
+$9.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$1.05M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$137K |
| 3 |
BWM
Baystate Wealth Management
Boston,
Massachusetts
|
-$19.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$14.9K |
| 5 |
EAM
Empirical Asset Management
Wellesley,
Massachusetts
|
-$9.2K |
CADL Hedge Fund Activity: Q4 2023 in Review
22 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q4 2023, worth a combined $5.92M — up 22% from $4.86M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CADL positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $21.1K. The largest seller was Franklin Resources, exiting entirely with an estimated $1.05M sold.
- 22 institutional investors held Candel Therapeutics (CADL) as of Q4 2023, up from 20 in Q3 2023.
- Funds reported $5.92M of Candel Therapeutics stock for Q4 2023, up 22% quarter-over-quarter.
- 4 funds opened new Candel Therapeutics positions in Q4 2023 and 2 closed out, a net change of +2 holders.
- The largest Candel Therapeutics buyer in Q4 2023 was Vanguard Group, an estimated $21.1K added.
- The largest Candel Therapeutics seller in Q4 2023 was Franklin Resources, an estimated $1.05M sold.
Based on aggregated 13F filings for Q4 2023.